{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:53:51Z","timestamp":1781304831809,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.diabres.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T22:34:50Z","timestamp":1448318090000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation"],"prefix":"10.1016","volume":"112","author":[{"given":"Lawrence A.","family":"Leiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina V.","family":"Shestakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya P.","family":"Trubitsyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milivoj","family":"Pileti\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhan","family":"Satman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2015.11.001_bib0170","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcjd.2013.02.055","article-title":"Type 2 diabetes mellitus management in Canada: is it improving","volume":"37","author":"Leiter","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.diabres.2015.11.001_bib0180","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. Diabetes Care, 1999\u20132010","volume":"368","author":"Ali","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0185","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/dc12-1759","article-title":"Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study","volume":"36","author":"Stone","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.11.001_bib0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.11.001_bib0195","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2015.11.001_bib0200","first-page":"S1","article-title":"Canadian Diabetes Association 2013 Clinical Practice Guidelines for the prevention and management of diabetes in Canada","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.diabres.2015.11.001_bib0205","series-title":"Type 2 diabetes: National Clinical Guideline for management in primary and secondary care (update)","author":"National Collaborating Centre for Chronic Conditions","year":"2008"},{"key":"10.1016\/j.diabres.2015.11.001_bib0210","first-page":"512","article-title":"NHG-Standard diabetes mellitus type 2 (derde herziening)","volume":"56","author":"Rutten","year":"2013","journal-title":"Huisarts Wet"},{"key":"10.1016\/j.diabres.2015.11.001_bib0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12020-013-9884-3","article-title":"Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy","volume":"44","author":"Majumdar","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.diabres.2015.11.001_bib0220","doi-asserted-by":"crossref","first-page":"e82880","DOI":"10.1371\/journal.pone.0082880","article-title":"Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"9","author":"Landman","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diabres.2015.11.001_bib0225","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1464-5491.1994.tb00256.x","article-title":"Glibenclamide vs gliclazide in type 2 diabetes of the elderly","volume":"11","author":"Tessier","year":"1994","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1463-1326.2011.01496.x","article-title":"Variations in tissue selectivity amongst insulin secretagogues: a systematic review","volume":"14","author":"Abdelmoneim","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2015.11.001_bib0235","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study","volume":"32","author":"Schramm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2015.11.001_bib0240","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Advance Collaborative Group Patel A","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0245","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","article-title":"Mortality risk among sulfonylureas: a systematic review and network meta-analysis","volume":"3","author":"Simpson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2015.11.001_bib0255","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1462-8902.2004.00404.x","article-title":"Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes","volume":"6","author":"Drouin","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2015.11.001_bib0260","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0265","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2015.11.001_bib0270","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study G","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0280","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2015.11.001_bib0285","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1505-6","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"The CONTROL Group","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2015.11.001_bib0290","series-title":"WHO Secretariat Should elderly patients with type 2 diabetes be treated with glibenclamide (glyburide) or different sulfonylurea?","author":"Chahal","year":"2013"},{"key":"10.1016\/j.diabres.2015.11.001_bib0295","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/archinte.166.17.1836","article-title":"Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0300","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/archinte.166.17.1802","article-title":"Improving medication adherence: challenges for physicians, payers, and policy makers","volume":"166","author":"O\u2019Connor","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabres.2015.11.001_bib0305","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1742-1241.2010.02544.x","article-title":"Patient adherence to medication requirements for therapy of type 2 diabetes","volume":"65","author":"Bailey","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2015.11.001_bib0310","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1185\/03007995.2013.821056","article-title":"Predictors of medication adherence in patients with type 2 diabetes mellitus","volume":"29","author":"Curkendall","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2015.11.001_bib0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1463-1326.2008.00882.x","article-title":"Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study","volume":"10","author":"Alvarez Guisasola","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2015.11.001_bib0320","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00125-002-0822-9","article-title":"Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes","volume":"45","author":"Cryer","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2015.11.001_bib0325","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1742-1241.2011.02797.x","article-title":"The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial","volume":"65","author":"Al Sifri","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2015.11.001_bib0330","first-page":"319","article-title":"A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study","volume":"10","author":"Hassanein","year":"2014","journal-title":"Vasc Health Risk Manage"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882271500457X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882271500457X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T12:14:25Z","timestamp":1656245665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882271500457X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":33,"alternative-id":["S016882271500457X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2015.11.001","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}